Immunoglobulin E (IgE) specific for Populus tremuloides pollen allergens (sIgE (Populus tremuloides))

Immunoglobulin E (IgE) antibodies specific for Populus tremuloides (Quaking Aspen) pollen allergens are the primary mediators of Type I hypersensitivity in sensitized individuals (PMID: 16001914). These antibodies are produced by B cells and subsequently bind to the high-affinity FcεRI receptor on the surface of mast cells and basophils (NCBI Bookshelf: NBK27117). Upon re-exposure to Aspen pollen, the allergens cross-link the surface-bound IgE, triggering the degranulation of these effector cells and the release of inflammatory mediators like histamine and leukotrienes. This physiological cascade results in the clinical symptoms of pollinosis, including allergic rhinitis, conjunctivitis, and potentially life-threatening asthma exacerbations (World Allergy Organization). Therapeutic management involves the use of anti-IgE monoclonal antibodies, such as Omalizumab, which sequester free IgE and downregulate receptor expression (PubChem CID: 16130453). Furthermore, allergen-specific immunotherapy (AIT) utilizes Populus tremuloides extracts to shift the immune response from a Th2-driven allergic state to a Th1/Treg-mediated tolerant state, often characterized by an increase in neutralizing IgG4 antibodies (PMID: 29055351).

Other names

Aspen pollen-specific IgEQuaking Aspen IgEPopulus tremuloides sIgEAnti-Populus tremuloides IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity FcεRI receptors on mast cells and basophils. Allergen-specific immunotherapy (AIT) works by inducing immune tolerance through the expansion of regulatory T cells and the induction of allergen-specific IgG4 antibodies which compete with IgE for allergen binding.